{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T07:09:13Z","timestamp":1771571353731,"version":"3.50.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Microbial involvement in sarcoidosis pathogenesis is suggested by the observation that histological findings in sarcoid granulomas are like those of leprosy, tuberculosis and parasitic infection. Some studies have shown that the lung microbiome in patients with sarcoidosis is different from healthy individuals. Results are conflicting, reporting an abundance or decrease in bacterial and fungal species. The altered composition of the microbiome in sarcoidosis can contribute to the formation of granulomas, typical lesions of the disease, through interactions with the host immune system. However, no single microbe has been clearly demonstrated as a cause of sarcoidosis, several microorganisms have been involved in the formation of granulomas and are under study. In fact, various microorganisms have been detected in sarcoid granulomas and in the tissue of different organs. Microorganisms were demonstrated at the genomic level and only a few studies showed microbial presence using bacteriological or proteomic methods. A possible microbial involvement in sarcoidosis pathogenesis is further supported by studies reporting innate immune system activation and increased inflammatory cytokines secretion. Of note, a meta-analysis involving over 6,000 patients identified a strong association between\n                    <jats:italic>Cutibacterium acnes<\/jats:italic>\n                    and\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    and sarcoidosis. Interestingly, some studies have compared microbiomes in sarcoidosis with chronic respiratory conditions like chronic obstructive pulmonary disease, asthma, interstitial lung disease, and occupational lung diseases. Little is known whether gut microbiota alteration plays a causal role in the development of these diseases or is a consequence of a shared risk factor profile. However, current evidence does not conclusively support the causative role of microbes in sarcoidosis. Furthermore, research is studying the role of intestinal microbiomes in sarcoidosis with some studies showing that the restoration of the intestinal microbiome could be a possible therapeutic approach. The aims of the review are: (1) to clarify microbial involvement in sarcoidosis pathogenesis, (2) to describe microbiota in lungs of patients with sarcoidosis and to compare the data with other interstitial lung diseases.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2026.1747012","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T06:41:43Z","timestamp":1771569703000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Gut microbiota and sarcoidosis: a concise review"],"prefix":"10.3389","volume":"13","author":[{"given":"Roberto G.","family":"Carbone","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Genoa","place":["Genoa, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Puppo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Genoa","place":["Genoa, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor F.","family":"Tapson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cedars-Sinai","place":["Los Angeles, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-1-60327-074-8_11","article-title":"Sarcoidosis","volume-title":"Pulmonary arterial hypertension and interstitial lung diseases","author":"Baughman","year":"2009"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.52305\/XGNW5068","article-title":"Microbiome and interstitial lung disease","volume-title":"Interstitial lung disease from diagnosis to treatment","author":"Carbone","year":"2022"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1164\/rccm.201006-0865CI","article-title":"A concise review of pulmonary sarcoidosis","volume":"183","author":"Baughman","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.52305\/XGNW5068","article-title":"A clinical approach to interstitial lung disease diagnosis","volume-title":"Interstitial lung disease from diagnosis to treatment","author":"Carbone","year":"2022"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1097\/MD.0000000000000121","article-title":"Sarcoidosis occurring after lymphoma: report of 14 patients and review of the literature","volume":"93","author":"London","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/CMR.0000000000000437","article-title":"Sarcoid-like reactions in patients receiving modern melanoma treatment","volume":"28","author":"Dimitriou","year":"2018","journal-title":"Melanoma Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1159\/000484596","article-title":"Pulmonary sarcoidosis activation following neoadjuvant pembrolizumab plus chemotherapy combination therapy in a patient with non-small cell lung cancer: a case report","volume":"10","author":"Fakhri","year":"2017","journal-title":"Case Rep Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","article-title":"Sarcoidosis-like reactions induced by checkpoint inhibitors","volume":"13","author":"Gkiozos","year":"2018","journal-title":"J Thorac Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40425-018-0323-0","article-title":"Granulomatous\/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients","volume":"6","author":"Tetzlaff","year":"2018","journal-title":"J Immunother Cancer"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/thoraxjnl-2012-202917","article-title":"Microbial communities in the respiratory tract of patients with interstitial lung disease","volume":"68","author":"Garzoni","year":"2013","journal-title":"Thorax"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41392-023-01722-y","article-title":"Lung microbiome: new insights into the pathogenesis of respiratory diseases","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1046\/j.1365-2796.2003.01073.x","article-title":"Is there a role for microorganisms in the pathogenesis of sarcoidosis?","volume":"253","author":"Du Bois","year":"2003","journal-title":"J Intern Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s40168-022-01362-4","article-title":"The lower airways microbiota and antimicrobial anti peptides indicate dysbiosis in sarcoidosis","volume":"10","author":"Knudsen","year":"2022","journal-title":"Microbiome"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/sji.12273","article-title":"Increased antifungal antibodies in bronchoalveolar lavage fluid and serum in pulmonary sarcoidosis","volume":"81","author":"Suchankova","year":"2015","journal-title":"Scand J Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00408-011-9280-9","article-title":"Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature","volume":"189","author":"Pena","year":"2011","journal-title":"Lung"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/thoraxjnl-2014-206291","article-title":"The clinical spectrum of pulmonary aspergillosis","volume":"70","author":"Kosmidis","year":"2015","journal-title":"Thorax"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/biomedicines13010144","article-title":"Gut-heart axis: microbiome involvement in restrictive cardiomyopathies","volume":"13","author":"Jaimez-Alvarado","year":"2025","journal-title":"Biomedicine"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"103247","DOI":"10.1016\/j.jaut.2024.103247","article-title":"The immunopathogenesis of sarcoidosis","volume":"149","author":"Miedema","year":"2024","journal-title":"J Autoimmun"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/MCP.0000000000000305","article-title":"Innate immunity in sarcoidosis pathobiology","volume":"22","author":"Chen","year":"2016","journal-title":"Curr Opin Pulm Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s43162-023-00199-z","article-title":"Hidden relationship between sarcoidosis and gut microbiota: recent evidence and future implications","volume":"35","author":"Farahat","year":"2023","journal-title":"Egypt J Intern Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.3390\/ijerph16101830","article-title":"Genetic variants associated with FDNY WTC-related sarcoidosis","volume":"16","author":"Cleven","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"595522","DOI":"10.3389\/fmed.2021.595522","article-title":"Role of microbiome in interstitial lung diseases","volume":"8","author":"Chioma","year":"2021","journal-title":"Frontiers Med (Lausanne)"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1038\/s41598-021-83524-2","article-title":"Comparative analysis of the alveolar microbiome in COPD, ECOPD, sarcoidosis, and ILD patients to identify respiratory illnesses specific microbial signatures","volume":"11","author":"Gupta","year":"2021","journal-title":"Sci Rep"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12931-019-1013-2","article-title":"The composition of the pulmonary microbiota in sarcoidosis \u2013 an observational study","volume":"20","author":"Becker","year":"2019","journal-title":"Respir Res"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3390\/life15071069","article-title":"Microbiome against the background of the complex aetiology in sarcoidosis \u2013 what do we already know?","volume":"15","author":"Szymanski","year":"2025","journal-title":"Life (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e0179980","DOI":"10.1371\/journal.pone.0179980","article-title":"Immunohistochemical identification of Propionibacterium acnes in granuloma and inflammatory cells of myocardial tissues obtained from cardiac sarcoidosis patients","volume":"12","author":"Asakawa","year":"2017","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.chest.2020.12.027","article-title":"Phase II investigation of the efficacy of antimycobacterial therapy in chronic pulmonary sarcoidosis","volume":"159","author":"Drake","year":"2021","journal-title":"Chest"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/archderm.137.1.69","article-title":"The use of tetracyclines for the treatment of sarcoidosis","volume":"137","author":"Bachelez","year":"2001","journal-title":"Arch Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"354","DOI":"10.36141\/svdld.v35i4.7061","article-title":"A common microbial signature is present in lower airways of interstitial lung diseases including sarcoidosis","volume":"35","author":"D\u2019Argenio","year":"2018","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"70328","DOI":"10.1002\/hsr2.70328","article-title":"Metagenonic analysis of lung microbiome in patients with interstitial lung diseases and sarcoidosis","volume":"8","author":"Takeuchi","year":"2025","journal-title":"Health Sci Rep"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1747012\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T06:41:45Z","timestamp":1771569705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1747012\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":31,"alternative-id":["10.3389\/fmed.2026.1747012"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1747012","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"article-number":"1747012"}}